Allergy Therapeutics LON:AGY the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today gave DirectorsTalk a trading update covering the first four months of the 2016 financial year.
Allergy Therapeutics’ Matthew Heath discusses the company’s background, the 93p valuation from Hardman & Co, the World Vaccine Congress and the US FDA trials in this exclusive interview with DirectorsTalk
Allergy Therapeutics Plc (LON:AGY) lead medical writer and principal scientist Dr Matthew Heath provides DirectorsTalk with some background to the company, shares his thoughts on the 93p per share valuation
Dr Murray Skinner, Chief Scientific Officer at Allergy Therapeutics LON:AGY, said: “Adjuvant discovery is experiencing a significant boost in investment from government bodies, such as the NIH who describe a significant
Allergy Therapeutics Plc provide information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with a special focus on allergy vaccination (also known as specific immunotherapy or
Allergy Therapeutics Plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. It has an underlying profitable and cash generative business despite its lead product being
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
